Frequency Therapeutics announced that it has dosed a first patient in the Phase 1b study of FX-345, the company’s second hearing restoration candidate for sensorineural hearing loss, or SNHL. FX-345 is a combination of two small molecules and, similar to Frequency’s lead hearing candidate FX-322, is designed to restore inner ear cells needed for hearing. However, FX-345 includes a more potent GSK3 inhibitor, a new chemical entity that may enable targeted drug exposure further into the cochlea. Future clinical studies will determine whether greater cochlear drug exposure can address additional populations of individuals with SNHL.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FREQ:
- Frequency Therapeutics management to meet virtually with Oppenheimer
- Frequency Therapeutics to hold investor webcast
- Frequency Therapeutics initiated with a Buy at Chardan
- Frequency Therapeutics reports Q3 EPS (55c), consensus (57c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue